A. Eberl

发表

5PSQ-056 Evaluation of oxaliplatin-specific neurotoxicity based on total cumulative dose

M. Sonc, M. Fortuna, J. Dolenc, 2018 .

Ustekinumab for Crohn’s disease: a nationwide real-life cohort study from Finland (FINUSTE)

R. Nissinen, E. Soini, M. Heikkinen, 2019, Scandinavian journal of gastroenterology.

Higher serum infliximab concentrations during induction predict short-term endoscopic response in patients with inflammatory bowel disease

P. Saavalainen, T. Sipponen, A. Eberl, 2022, European journal of gastroenterology & hepatology.

A nationwide real-world study on dynamic ustekinumab dosing and concomitant medication use among Crohn’s disease patients in Finland

E. Soini, M. Heikkinen, T. Hallinen, 2021, Scandinavian Journal of Gastroenterology.

Bacterial and fungal profiles as markers of infliximab drug response in inflammatory bowel disease.

K. Korpela, A. Salonen, P. Saavalainen, 2020, Journal of Crohn's & colitis.

Switching maintenance infliximab therapy to biosimilar infliximab in inflammatory bowel disease patients

T. Pahikkala, P. Arkkila, M. Blom, 2017, Scandinavian journal of gastroenterology.

Health-related quality of life and costs of switching originator infliximab to biosimilar one in treatment of inflammatory bowel disease

R. Roine, P. Arkkila, M. Blom, 2020, Medicine.

P685 Switching from originator-infliximab to biosimilar-infliximab has no influence on health-related quality of life and clinical disease activity among patients with inflammatory bowel disease.

R. Roine, P. Arkkila, M. Blom, 2017, Journal of Crohn's & colitis.

Chronic Inflammation Might Protect Hemodialysis Patients From Severe COVID-19

T. Pieber, M. Brodmann, P. Eller, 2022, Frontiers in Immunology.

Objectively assessed disease activity and drug persistence during ustekinumab treatment in a nationwide real-world Crohn’s disease cohort

R. Nissinen, E. Soini, M. Heikkinen, 2020, European journal of gastroenterology & hepatology.